The US Food and Drug Administration has accepted for review a submission from American biotech VBI Vaccines (Nasdaq: VBIV), for a hepatitis B vaccine candidate.
The company, which is developing next-generation infectious disease and immuno-oncology vaccines, wants to market its 3-antigen vaccine for the prevention of infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.
The submission is backed by data from two Phase III studies – PROTECT and CONSTANT – as well as other relevant data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze